Preservation of endogenous antioxidant activity and inhibition of lipid peroxidation as common mechanisms of antiatherosclerotic effects of vitamin E, lovastatin and amlodipine

Journal of the American College of Cardiology

Volumn 30, Issue 2, 1997, Pages 569-575

  Chen, Liying ^a   Haught, W Herbert ^a   Yang, Baichun ^a   Saldeen, Tom G P ^b   Parathasarathy, Sampath ^c   Mehta, Jawahar L ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b UPPSALA UNIVERSITY   (Sweden)

^c EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; AMLODIPINE; CINNARIZINE; LACIDIPINE; MEVINOLIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; CALCIUM CELL LEVEL; CALCIUM TRANSPORT; CHOLESTEROL DIET; CONTROLLED STUDY; DRUG EFFECT; ENZYME INHIBITION; HYPERCHOLESTEROLEMIA; LIPID PEROXIDATION; NONHUMAN; OXIDATION; PRIORITY JOURNAL;

AMLODIPINE; ANIMALS; ANTICHOLESTEREMIC AGENTS; ANTIOXIDANTS; ARTERIOSCLEROSIS; CALCIUM CHANNEL BLOCKERS; DIET, ATHEROGENIC; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIPID PEROXIDATION; LOVASTATIN; RABBITS; SUPEROXIDE DISMUTASE; VITAMIN E;

EID: 0030752323     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0735-1097(97)00158-7     Document Type: Article

References (40)

1. Lipid Research Clinics Program. The lipid research clinics coronary primary prevention trial results. JAMA 1984;251:351-64; 365-74.
2. Tasaki H, Yamashita K, Nakashima Y, Kuroiwa A, Tulenko TN. Increase in intracellular calcium ion in smooth muscle cells induced by low-density lipoprotein. Gerontology. 40:(Suppl 2):1994;23-28.
3. Witztum JL, Steinberg D. Role of oxidized low density lipoprotein in atherogenesis. J Clin Invest. 88:1991;1785-1792.
4. Halliwell B. Oxidants and human disease some new concepts . FASEB J. 1:1987;358-364.
5. Bierenbaum ML, Reichstein RP, Bhagavan HN, Watkins TR. Relationship between serum lipid peroxidation products in hypercholesterolaemic subjects and vitamin E status. Biochem Mol Biol Int. 28:1992;57-66.
6. Stewart-Lee AL, Forster LA, Nourooz-Zadeh J, Ferns GAA, Anggård EE. Vitamin E protects against impairment of endothelium-mediated relaxations in cholesterol-fed rabbits. Arterioscler Thromb Vasc Biol. 14:1994;494-499.
7. Polette A, Blache D. Effect of vitamin E on acute iron load-potentiated aggregation, serotonin, calcium uptake and thromboxane biosynthesis in rat platelets. Atherosclerosis. 96:1992;171-179.
8. Grundy SM. HMG-CoA reductase inhibitors for the treatment of hypercholesterolemia. N Engl J Med. 319:1988;24-33.
9. Henwood JM, Heel RC. Lovastatin a preliminary review of its pharmacodynamic properties and therapeutic use in hyperlipidaemia . Drugs. 36:1988;429-454.
10. Nayler WG. Calcium antagonists and atherosclerosis. Calcium Antagonists. 1988;235-247 Academic Press, London.
11. 2+ channel blockers . Atherosclerosis. 88:1991;109-132.
12. Aviram M, Dankner G, Cogan U, Hochgraf E, Brook JG. Lovastatin inhibits low-density lipoprotein oxidation and alters its fluidity and uptake by macrophages in vitro and in vivo studies . Metabolism. 41:1992;229-235.
13. Van Amsterdam FThM, Roveri A, Maiorino M, Ratti E, Ursini F. Lacidipine a dihydropyridine calcium antagonist with antioxidant activity . Free Radic Biol Med. 12:1992;183-187.
14. Fernandes AC, Filipe PM, Coelho H, Manso CF. The inhibition of lipid peroxidation by cinnarizine. Biochem Pharmacol. 41:1991;709-714.
15. Rankin SM, Parathasarathy S, Steinberg D. Evidence for a dominant role of lipoxygenase(s) in the oxidation of LDL by mouse peritoneal macrophages. J Lipid Res. 32:1991;449-456.
16. Ohkawa H, Ohishi N, Yagi K. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem. 95:1979;351-358.
17. Haglund O, Vostarinen RL, Wallin R, Wileell L, Saldeen TGP. The effects of fish oil on triglycerides, cholesterol, fibrinogen and malondialdehyde in humans supplemented with vitamin E. J Nutr. 121:1991;165-169.
18. Marklund S, Marklund G. Involvement of the superoxide anion radical in the autoxidation of pyrogallol and a convenient assay for superoxide dismutase. Eur J Biochem. 74:1974;469-474.
19. Chand N, Pillar J, Diamantis W, Sofia RD. In vitro inhibition of allergic histamine release by calcium antagonists. Eur J Pharmacol. 107:1985;353-358.
20. Glavind J, Hartman S, Clemensen J, Jessen KE, Damt H. Studies on the role of lipoperoxides in human pathology. II. The presence of peroxidized lipids in the atherosclerotic aorta. Acta Pathol Microbiol Scand. 30:1952;1-6.
21. Knight JA, Smith SE, Kinder VE, Anstall HB. Reference interval for plasma lipoperoxides age-, sex-, and specimen-related variations . Clin Chem. 33:1987;2289-2291.
22. Luoma PV, Stengard J, Korpela H, Rautio A, Sotaniemi EA, Suvanto E, Marniemi JJ. Lipid peroxides, glutathione peroxidase, high density lipoprotein subfractions and apolipoproteins in young adults. J Intern Med. 227:1990;287-289.
23. Lavy A, Brook JG, Dankner G, Ben-Amotz A, Aviram M. Enhanced in vitro oxidation of plasma lipoproteins derived from hypercholesterolemic patients. Metabolism. 40:1991;794-799.
24. Mitchinson MJ, Ball RY, Carpenter KL. Ceroid accumulation by murine peritoneal macrophages exposed to artificial lipoproteins ultrastructural observations . Br J Exp Pathol. 69:1988;43-56.
25. Steinberg D. Clinical trials of antioxidants in atherosclerosis are we doing the right thing? Lancet. 346:1995;36-38.
26. Esterbauer H, Jurgens G, Quehenber O, Koller E. Autoxidation of human low density lipoprotein loss of polyunsaturated fatty acids and vitamin E and generation of aldehydes . J Lipid Res. 28:1987;495-509.
27. Zimmerman GA, Prescott SM, McIntyre TM. Endothelial cell interactions with granulocytes tethering and signaling molecules . Immunol Today. 13:1992;93-99.
28. Carpenter KLH, Taylor SE, van der Veen C, Williamson BK, Ballantine JA, Mitchinson MJ. Lipids and oxidised lipids in human atherosclerotic lesions at different stages of development. Biochim Biophys Acta. 1256:1995;141-150.
29. Riemersma RA. Coronary heart disease and vitamin E. Lancet. 347:1996;776-777.
30. Stephens NG, Parsons A, Schofield PM, et al. Randomised controlled trial of vitamin E in patients with coronary disease Cambridge Heart Antioxidant Study (CHAOS) . Lancet. 347:1996;781-786.
31. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease the Scandinavian Simvastatin Survival Study (4S) . Lancet. 344:1994;1383-1385.
32. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med. 333:1995;1301-1307.
33. Waters D, Lesperance J, Francetich D, et al. A controlled clinical trial to assess the effect of calcium channel blocker on the progression of coronary atherosclerosis. Circulation. 82:1990;1940-1953.
34. Zhu BQ, Sun YP, Sievers RE, Isenberg WM, Moorehead TJ, Parmley WW. Effects of etidronate and lovastatin on the regression of atherosclerosis in cholesterol-fed rabbits. Cardiology. 85:1994;370-377.
35. Saitoh K, Mori T, Kasai H, Nagayama T, Ohbayashi S. Anti-atheromatous effects of femofibrate, a hypolipidemic drug II anti-atheromatous effects are independent of its hypolipidemic effect in hereditary hyperlipidemic rabbits . Nippon Yakurigaku Zasshi. 106:1995;51-60.
36. Bokoch GM, Prossnitz V. Isoprenoid metabolism is required for stimulation of the respiratory burst oxidase of HL-60 cells. J Clin Invest. 89:1992;402-408.
37. Giroux LM, Davignon J, Naruszewicz M. Simvastatin inhibits the oxidation of low-density lipoproteins by activated human monocyte-derived macrophages. Biochim Biophys Acta. 1165:1993;335-338.
38. Bereta M, Bereta J, Cohen S, Cohen MC. Low density lipoprotein inhibits accumulation of nitrites in murine brain endothelial cell cultures. Biochem Biophys Res Commun. 186:1992;315-320.
39. Noronha-Dutra AA, Steen-Dutra EM, Woolf N. An antioxidant role or calcium antagonists in the prevention of adrenaline-mediated myocardial and endothelial damage. Br Heart J. 65:1991;322-325.
40. 2+ channel blockers . Atherosclerosis. 88:1991;109-132.